Pro-Pharmaceuticals completes enrollment in stage 1 of phase 2 colorectal cancer trial

By Lisa Kerner

Erie, Pa., March 30 - Pro-Pharmaceuticals, Inc. said it completed patient enrollment in stage l of its Simon two-stage designed phase 2 trial for third- and fourth-line treatment of colorectal cancer patients.

In the phase 2 study, patients with colon cancer, which has spread despite treatment, are receiving Davanat plus 5-Fluorouracil (5-FU) in monthly cycles for at least two cycles or until their disease progresses, according to a company news release.

The patients are also refractory to 5FU and have a minimum of 12 weeks to live.

Dosing of patients began in May 2005 with preliminary results expected in the second quarter of this year.

Pro-Pharmaceuticals said the study is designed to evaluate the safety and efficacy of Davanat plus 5-FU to shrink tumors or prevent growth.

Davanat, a proprietary polysaccharide polymer, enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells.

Pro-Pharmaceuticals discovers, develops and commercializes carbohydrate-based therapeutic compounds for treatment of cancer, as well as liver, microbial, cardiovascular and inflammatory diseases, and viral infections. The company is based in Newton, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.